Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>PTC209 HBr

PTC209 HBr Sale

目录号 : GC12147

A BMI-1 inhibitor

PTC209 HBr Chemical Structure

Cas No.:1217022-63-3

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥977.00
现货
2mg
¥609.00
现货
5mg
¥767.00
现货
10mg
¥1,208.00
现货
50mg
¥3,591.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment:

MTT assays are used to assess proliferation of Abrams, D17, and Moresco canine OSA cells following treatment of PTC-209 alone and in combination with Dox or Carbo. 500 cells are seeded in 96 well plates with DMEM/10%FBS and allowed to adhere overnight (16-18 hrs). For single treatment PTC-209 experiments, cells are incubated with drug for 72hrs at final concentrations of 0, 200, 300, 400, 500, and 600nM. For combination treatment experiments, cells are incubated with drug(s) for 72hrs at the following final concentrations: PTC-209 (0, 100, 200, and 500 nM), Dox (0, 3, and 30 nM), Carbo (0, 3, and 30 μM). Vehicle controls include DMSO (PTC-209), 0.9% saline (Dox), and water (Carbo). Additional controls included untreated (UT) cells (no veh or drug) and wells containing media (DMEM/10%FBS) alone (to assess background absorbance). Briefly, MTT solution is added to each well at a final conc. of 0.5mg/mL and incubated at 37°C for 4hrs. 200uL of DMSO is added to dissolve formazin crystals and absorbance is measured at 570nM and 630nM (reference wavelength) using a spectrophotometer (Spectramax 190). 6 wells per group are used for PTC-209 single treatment experiments, and 4 wells per group are used for combination treatment experiments, and all experiments are repeated twice. Statistical analysis is performed using 2-way ANOVA with Tukey’s multiple comparisons test.

Animal experiment:

Mice[1] For the experiments where mice are dosed with the drug in vivo, tumor cells are injected subcutaneously into nude mice (male, aged 8-10 weeks), and when the tumors reach an approximate 0.2 cm3 volume, PTC-209 is administered subcutaneously once a day at a dose of 60 mg per kg body weight (control animals received equal volumes of vehicle, 14% DMSO, 36% polyethylene glycol 400 and 50% polypropylene glycol). Tumor volume measurements are recorded every 3-7 d until the endpoint is reached.

References:

[1]. Kreso A, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014 Jan;20(1):29-36.
[2]. Christian Mayr, et al. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget. 2016 Jan 5; 7(1): 745-758.
[3]. Shahi MH, et al. BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance. PLoS One. 2015 Jun 25;10(6):e0131006.

产品描述

PTC-209 HBr is the hydrobromide salt of PTC-209, a potent and selective BMI-1 inhibitor (IC50 = 0.5μM). It irreversibly impairs the colorectal tumor growth. [1]
BMI-1 is a component of polycomb repressive complex 1 (PRC1) and act as an epigenetic chromatin modifier for a variety of genes. [1]
PTC-209 inhibited both UTR-mediated reporter expression and endogenous BMI-1 expression in HCT116 (human colorectal cell) and HT1080 (human fibrosarcoma tumor cell) in a dose dependent manner. In addition, the inhibitory effect of PTC-209 was not from its cytotoxicity. PTC-209 also specifically reduced PRC1 activity. [1]
Viable colorectal cancer cell samples treated with PTC-209 ex vivo were injected back to the recipient mice in vivo, the mice exhibited reduced or no tumor growth comparing with the control groups. Thus PTC-209 irreversibly impaired colorectal cancer-initiating cells. Furthermore, in contrast with the control groups, tumor volume was significantly reduced in the colorectal tumor cell transplanted mice following PTC-209 administration. [1]
References:
[1] Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T, Cao L,Baiazitov R, Du W, Sydorenko N, Moon YC, Gibson L, Wang Y, Leung C, Iscove NN,Arrowsmith CH, Szentgyorgyi E, Gallinger S, Dick JE, O'Brien CA. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014 Jan;20(1):29-36.

Chemical Properties

Cas No. 1217022-63-3 SDF
化学名 N-(2,6-dibromo-4-methoxyphenyl)-4-(2-methylimidazo[1,2-a]pyrimidin-3-yl)thiazol-2-amine hydrobromide
Canonical SMILES BrC1=CC(OC)=CC(Br)=C1NC2=NC(C3=C(C)N=C4N3C=CC=N4)=CS2.Br
分子式 C17H13Br2N5OS.HBr 分子量 576.10
溶解度 ≥ 22.9mg/mL in DMSO with gentle warming 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.7358 mL 8.679 mL 17.3581 mL
5 mM 0.3472 mL 1.7358 mL 3.4716 mL
10 mM 0.1736 mL 0.8679 mL 1.7358 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置